Exploring China’s Indigenous Drug Anlotinib: A Beacon of Hope for Digestive Tract Tumor Patients

Exploring China’s Indigenous Drug Anlotinib: A Beacon of Hope for Digestive Tract Tumor Patients

China’s Indigenous Drug

In the continuous advancement of medicine, Anlotinib combined chemotherapy is emerging as a frontline therapy for advanced, unresectable liver metastases from digestive tract tumors. Let’s delve into the latest findings from a phase II clinical trial initiated by researchers from the Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital.

ALTER-G-001 Cohort C: A Glimmer of Hope

As of November 13, 2023, a total of 41 patients were enrolled in ALTER-G-001 Cohort C, comprising mainly 29 cases of pancreatic cancer, 6 cases of gastric cancer, and 5 cases of biliary tract cancer. These patients had a median age of 64 years, with 63.4% being male, and 92.7% having an ECOG performance status of 1. 56.1% of patients had liver metastases only. All patients received Anlotinib combined with standard chemotherapy. The efficacy assessment revealed partial responses in 16 patients and stable disease (with tumor shrinkage in 14 patients) in 17 patients, resulting in an objective response rate (ORR) of 42.1% and a disease control rate (DCR) of 86.8%. Among evaluable pancreatic cancer patients, the ORR and DCR were 42.3% and 88.5%, respectively. These data underscore the significant efficacy of Anlotinib in treating digestive tract tumors.

Safety and Tolerability

Regarding safety, 39 patients experienced treatment-related adverse events (TEAEs), with 53.7% of patients experiencing ≥Grade 3 TEAEs. Major adverse events included neutropenia (19.5%), leukopenia (14.6%), and thrombocytopenia (9.8%). However, despite some adverse events, the overall safety profile of Anlotinib combined chemotherapy remains acceptable.

Looking Ahead

Anlotinib, developed independently by the Chinese pharmaceutical company CTTQ PHARMA, is changing the treatment landscape for patients with advanced liver metastases from digestive tract tumors. Apart from pancreatic cancer, Anlotinib is undergoing clinical trials for various cancers, including non-small cell lung cancer, soft tissue sarcoma, gastric cancer, colorectal cancer, medullary thyroid carcinoma, differentiated thyroid carcinoma, and esophageal squamous cell carcinoma. This brings more hope and options for patients.

Conclusion

Anlotinib combined chemotherapy as a frontline treatment demonstrates good efficacy and acceptable safety for patients with advanced liver metastases from digestive tract tumors, bringing a ray of hope. We look forward to further research on this therapy and more patients benefiting from it in the future. May every patient find healing and hope in the progress of medicine.

We have access to medical resources from all cancer hospitals in China and can assist patients in receiving treatment from the best and top-tier oncologists in the CHINA.

doctor.huang@globecancer.com

WhatsApp：+8613717959070

#Anlotinib #DigestiveTractTumors #CancerTreatment #MedicalAdvancements